Study Name Principal Investigator
(ACCUTE) Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI) ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections) Young, Lester
(CD12) A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19) Islam, Shaheen
(EB05) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Eb05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients with Covid-19 Taskar, Varsha
(MEDLEY) A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children Patel, Pinkal
DEBIO: 1450-BJI-205: Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability and Efficacy of Afabicin IV/oral in the Treatment of Patients with Bone or Joint Infection due to Staphylococcus Vazquez, Jose
OASIS: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisomeŽ followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species Huggett, Ashley
ReSTORE: A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia and/or Invasive Candidiasis Vazquez, Jose
RESEARCH. INNOVATION. DISCOVERY.
Augusta University
Research
AU Health
Stay Informed
Get updates on new trials and more
(706)721-6582 © Augusta University 1120 15th Street Augusta, GA 30912